



ASX ANNOUNCEMENT

27 OCTOBER 2017

CANN GROUP GRANTED CANNABIS IMPORT / EXPORT LICENCE

27 October 2017 – Cann Group Limited (ASX: CAN) is pleased to announce it has been granted a licence to import and/or export cannabis genetics and medicinal cannabis products by the Australian Government Department of Health, through the Office of Drug Control (ODC).

As a holder of this licence, the Company can now apply for a permit to export raw cannabis material and cannabis oil for analytical testing. The Company intends to utilise the analytical services of Anandia Laboratories in Canada to complement the capabilities available to the Company in Australia (subject to the granting of an export permit and reciprocal Canadian import approvals).

The licence also allows the Company to apply for a permit to import cannabis genetics and medicinal cannabis products from legal international sources.

Cann Group is working closely with Canadian companies Aurora Cannabis and Anandia Laboratories to identify suitable genetics and medicinal cannabis products for inclusion in an import permit application. The Company intends to submit this as a matter of priority to facilitate the process of obtaining export approvals with Health Canada.

Cann Group CEO Peter Crock said: “The granting of this import/export licence is an important milestone in the Company’s goal of building a genetic database of locally and internationally sourced cannabis strains for cultivation under its medicinal cannabis licence, while facilitating the development of a plant breeding program under its cannabis research licence.

“Similarly, the import/export licence is a key step in the Company’s plans to import medicinal cannabis products for supply to Australian patients to complement the locally manufactured products that use cannabis cultivated by Cann Group.”

For further information please contact:

Peter Crock
Cann Group Limited
+61 (0) 3 9095 7088
contact@canngrouponlimited.com

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – Canada’s second largest listed medicinal cannabis company – is a cornerstone investor in Cann, with a 19.9% shareholding.

For personal use only